20 December 2011 - US Selexys Pharmaceuticals said yesterday it had finalised a Phase I trial of its lead sickle cell compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

The placebo-controlled, double-blind, ascending single dose and multiple dos...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up